{"title":"Anticholinergic burden in older patients presenting with hip fracture in Brunei Darussalam","authors":"Muhammad Amirsalman Nor Azman , Chia Wei Tan","doi":"10.1016/j.afos.2025.08.040","DOIUrl":"10.1016/j.afos.2025.08.040","url":null,"abstract":"","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 3","pages":"Page 13"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145044484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Addressing challenges in osteoporosis management in Vietnam","authors":"Tuan V. Nguyen","doi":"10.1016/j.afos.2025.08.043","DOIUrl":"10.1016/j.afos.2025.08.043","url":null,"abstract":"","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 3","pages":"Page 14"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145048107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cornelius Sebastian Fischer , Till Ittermann , Sarah Kalmbach , Moritz Herbst , Tina Histing , Jörn Lange , Anke Hannemann
{"title":"Are there associations between bone turnover and hip geometry in the general population?","authors":"Cornelius Sebastian Fischer , Till Ittermann , Sarah Kalmbach , Moritz Herbst , Tina Histing , Jörn Lange , Anke Hannemann","doi":"10.1016/j.afos.2025.05.007","DOIUrl":"10.1016/j.afos.2025.05.007","url":null,"abstract":"<div><h3>Objectives</h3><div>While impaired bone remodeling contributes to osteoporosis and probably to osteoarthritis, the relations between bone turnover and key hip geometry measures such as center-edge angle (CE), neck-shaft angle (NSA) or alpha angle remain unknown. We here examined the presence of associations between two bone turnover markers with hip geometric measures in adults from the general population.</div></div><div><h3>Methods</h3><div>Data from 2037 participants (50% women) in the Study of Health in Pomerania-TREND were examined. Hip geometric parameters were obtained using magnetic resonance imaging. Serum concentrations of carboxy-terminal telopeptide of Type I collagen (CTX, bone resorption) and intact amino-terminal propeptide of Type I procollagen (P1NP, bone formation) were measured to assess bone turnover.</div></div><div><h3>Results</h3><div>In sex-specific linear regression models adjusted for age, body mass index and physical inactivity, positive associations between CTX or P1NP and CE and inverse associations with NSA were detected. The latter were restricted to men. Thus, an increase in bone formation or resorption is related to less dysplastic (both sexes). Additionally, men with more valgus hips have lower bone turnover markers. For the alpha angle, no significant association was present.</div></div><div><h3>Conclusions</h3><div>The observed associations between bone turnover markers and hip geometry confirm the presence of relevant relations between bone properties and hip geometry. This knowledge may aid in detection of vulnerable groups with respect to osteoarthritis and fracture risk.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 50-56"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hunkyung Kim , Jiwan Kim , Chahee Lee , Seohee Kim
{"title":"Nutrition and exercise for sarcopenia treatment","authors":"Hunkyung Kim , Jiwan Kim , Chahee Lee , Seohee Kim","doi":"10.1016/j.afos.2025.05.008","DOIUrl":"10.1016/j.afos.2025.05.008","url":null,"abstract":"<div><div>Sarcopenia, the age-related loss of muscle mass, strength, and performance, is a significant concern in the aging population. Despite extensive research, no consensus exists on its prevention and treatment. Sarcopenia increases the risk of functional disability, falls, hospitalization, long-term care, morbidity, and mortality among older adults.</div><div>Currently, no approved pharmacological treatments for sarcopenia exist, making exercise and nutrition the most effective interventions. Evidence indicates that targeted exercise reduces risk factors, preventing or treating sarcopenia in older adults. Progressive, moderate-intensity exercise, alone or combined with nutritional supplementation, is recommended to mitigate muscle deterioration associated with aging. While non-pharmacological interventions are the primary approach, conflicting evidence exists regarding the most effective exercise and nutrition strategies. This review highlights that single intervention, such as exercise or nutritional supplementation alone, provide limited benefits for preventing or treating sarcopenia. In contrast, combined interventions, comprehensive exercise training and nutritional supplementation, effectively improve clinical indicators, including muscle mass, strength, and gait speed, in older adults with sarcopenia.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 54-64"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hypophosphatasia in childhood: Diagnosis to management","authors":"Minji Im, Sung Yoon Cho","doi":"10.1016/j.afos.2025.05.003","DOIUrl":"10.1016/j.afos.2025.05.003","url":null,"abstract":"<div><div>Hypophosphatasia (HPP) is a rare inherited metabolic bone disorder caused by loss-of-function mutations in the <em>ALPL</em> gene, leading to deficient activity of tissue-nonspecific alkaline phosphatase (TNSALP). HPP is diagnosed based on a combination of clinical features, laboratory findings, radiographic findings, and DNA analysis identifying a pathogenic variant of <em>ALPL</em>. Based on the clinical heterogeneity of HPP, the diagnosis of HPP is very challenging. However, the introduction of asfotase alfa, a bone-targeted recombinant TNSALP, has improved the prognosis. Early diagnosis of HPP is essential for timely initiation of enzyme replacement therapy (ERT). This review aims to provide an updated current knowledge on the genetic basis, pathophysiology, epidemiology, clinical classification, diagnosis, and management of HPP, with particular emphasis on ERT and emerging diagnostic approaches.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 38-42"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Byeong-Don Min , Chae Young Hwang , Doyeong Kim , Sang-Yun Kim , Jayasinghage Nirmani Chathurangika Jayasinghe , Minh Nhat Tran , Sang-Min Park , Ki-Sun Kwon
{"title":"Advancing muscle aging and sarcopenia research through spatial transcriptomics","authors":"Byeong-Don Min , Chae Young Hwang , Doyeong Kim , Sang-Yun Kim , Jayasinghage Nirmani Chathurangika Jayasinghe , Minh Nhat Tran , Sang-Min Park , Ki-Sun Kwon","doi":"10.1016/j.afos.2025.05.002","DOIUrl":"10.1016/j.afos.2025.05.002","url":null,"abstract":"<div><div>Sarcopenia, defined as a decline of muscle mass and function with aging, poses significant health challenges. This decline is driven by multiple factors including cellular dysfunction, mitochondrial impairments, oxidative stress, and chronic inflammation, all of which collectively disrupt muscle homeostasis and regeneration. Despite the lack of approved treatments for sarcopenia, the search for effective therapies continues as various pharmacological interventions are currently in the early stage of development. Recent advances in transcriptomics have enhanced our understanding of the molecular and cellular mechanisms underlying skeletal muscle aging. In particular, spatial transcriptomics (ST) has revolutionized the field of sarcopenia research by capturing the spatial context of gene expression to uncover site-specific regulation and cellular interactions within tissues. In this review, we explore the current knowledge of sarcopenia, the mechanisms underlying muscle aging, and recent developments in therapeutic strategies. Furthermore, we examine recent studies employing ST that have provided critical insights into the spatial heterogeneity of muscle aging and atrophy, revealing novel cellular and molecular targets for intervention. By connecting muscle pathophysiology with spatial information, ST holds promise for guiding the development of novel sarcopenia therapies, ultimately improving outcomes for aging populations worldwide.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 22-31"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sarcopenic obesity in the Asia-Pacific region: Epidemiology, risk factors, and management","authors":"Chun-Feng Huang , Chih-Hsing Wu","doi":"10.1016/j.afos.2025.05.001","DOIUrl":"10.1016/j.afos.2025.05.001","url":null,"abstract":"<div><div>Sarcopenic obesity (SO), characterized by the concurrent presence of sarcopenia and obesity, is an emerging public health challenge in the Asia–Pacific region. With rapid population aging and increasing obesity rates, the prevalence of SO is increasing, particularly among individuals over 60 years of age. This condition results from a complex interplay of muscle loss, fat accumulation, chronic inflammation, hormonal changes, and metabolic dysregulation, leading to heightened risks of frailty, disability, cardiovascular disease, and mortality.</div><div>Region-specific risk factors, including dietary transitions, reduced physical activity, and socioeconomic disparities, further contribute to its increasing prevalence. While pharmacological options are under investigation, lifestyle modifications remain the cornerstone of prevention and management. Regular resistance training, adequate protein intake, and balanced nutrition are essential for preserving muscle mass while promoting fat reduction. Community-based interventions, such as structured exercise programs, public health campaigns, and urban planning that encourage active aging, are crucial for sustainable long-term outcomes.</div><div>The current inconsistency in diagnostic criteria has led to numerous challenges, highlighting the urgent need for consensus. In addition, targeted policies focusing on nutritional education, elderly friendly infrastructure, and access to preventive healthcare are essential to alleviating the burden of SO. A comprehensive approach that integrates lifestyle interventions, clinical advancements, and supportive policies is crucial for effectively addressing the growing impact of SO in the Asia–Pacific region and improving health outcomes for the aging population.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 40-49"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bone-muscle interactions","authors":"Hiroshi Kaji","doi":"10.1016/j.afos.2025.04.001","DOIUrl":"10.1016/j.afos.2025.04.001","url":null,"abstract":"<div><div>Bone and skeletal muscle jointly govern motor function, working in coordination as anatomically adjacent organs, and collaborate with through mechanical interactions. Bone and muscle cells are both derived from common mesenchymal stem cells. Muscle tissues reportedly support fracture healing and bone repair. Common factors affect muscle and bone simultaneously, and sarcopenia and osteoporosis are complications of various diseases. Research on bone-muscle interactions has progressed in the past 15 years, and clinical evidence has confirmed that a relationship exists between sarcopenia and osteoporosis. Numerous myokines or osteokines play a role in bone-muscle interactions, and the involvement of extracellular vesicles has also been suggested. Research on bone-muscle interactions may translate into clinical applications for the treatment of sarcopenia and osteoporosis.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 32-39"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jun Lang , Vivek Kumar Morya , Mi-Kyung Kwak , Sin-Hye Park , Kyu-Cheol Noh
{"title":"Molecular crosstalk in SP7-mediated osteogenesis: Regulatory mechanisms and therapeutic potential","authors":"Jun Lang , Vivek Kumar Morya , Mi-Kyung Kwak , Sin-Hye Park , Kyu-Cheol Noh","doi":"10.1016/j.afos.2025.04.003","DOIUrl":"10.1016/j.afos.2025.04.003","url":null,"abstract":"<div><div>SP7, also known as Osterix, is a zinc finger-containing transcription factor, plays a crucial role in osteoblast differentiation and bone formation. This review examines the molecular mechanisms underlying SP7's regulatory functions, highlighting its interactions with key signaling pathways such as BMP-SMAD, Wnt/β-catenin, and HIF-1α. SP7 acts downstream of RUNX2 to regulate osteogenic gene expression, including collagen Type I Alpha 1 (COL1A1), alkaline phosphatase (ALP) and osteocalcin (OCN). The review also explores the role of post-translational modifications, such as phosphorylation and ubiquitination, in modulating SP7's stability and activity. Emerging therapeutic strategies targeting SP7, including gene editing, RNA-based approaches, and small-molecule modulators, are discussed as innovative solutions for treating osteoporosis and other skeletal disorders. The potential for future research into SP7's interactions with non-coding RNAs and angiogenesis pathways is emphasized, underscoring its significance in skeletal health and regenerative medicine. This comprehensive overview consolidates current knowledge of SP7's molecular functions, therapeutic potential, and its pivotal role in bone biology.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 31-37"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}